Drug-induced immune hemolytic anemia sales will rise through 2036, driven by hospital based management at 72.1% of the application segment in 2026. The market is set to reach USD 9.3 billion by 2026-end and USD 16.6 billion by 2036, creating an incremental opportunity of USD 7.34 billion between 2026 and 2036.